Truist Securities raises Stryker stock price target to $415 on solid results

Published 04/08/2025, 17:12
Truist Securities raises Stryker stock price target to $415 on solid results

Investing.com - Truist Securities raised its price target on Stryker (NYSE:SYK) to $415.00 from $410.00 on Monday, while maintaining a Hold rating on the medical technology company’s stock. According to InvestingPro data, analysts have set price targets ranging from $316 to $465, with 15 analysts recently revising their earnings estimates upward.

The price target adjustment follows Stryker’s double-digit revenue and earnings per share beat in its second quarter results, which prompted the company to raise its own guidance. The company, currently valued at $145.6 billion, has demonstrated strong performance with 11.4% revenue growth over the last twelve months. InvestingPro analysis indicates the stock is trading above its Fair Value, with 13 additional exclusive insights available to subscribers.

Truist noted some minor concerns including NARI destocking, softer knee growth, and longer than expected medical supply constraints, but characterized these issues as temporary.

The firm highlighted Stryker’s progress toward delivering 100 basis points of margin expansion in 2025 on approximately 10% organic revenue growth, describing the company as a high-quality large-cap with a diversified revenue profile and above-peer revenue and earnings growth.

Despite the positive assessment, Truist maintained its Hold rating, indicating it prefers other large-cap companies in its coverage universe with faster growth prospects.

In other recent news, Stryker Corporation announced its second-quarter earnings for 2025, surpassing analyst expectations. The company reported an earnings per share (EPS) of $3.13, which exceeded the forecasted $3.07, resulting in a 1.95% surprise. Additionally, Stryker’s revenue reached $6.02 billion, outperforming the anticipated $5.94 billion. These results highlight a positive performance for the quarter. Despite the strong earnings and revenue figures, Stryker’s stock experienced a decline during regular trading hours. However, there was a slight recovery in aftermarket trading. These developments are part of the latest updates for the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.